These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12837841)

  • 1. Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Hopper JL; Baron JA
    J Natl Cancer Inst; 2003 Jul; 95(13):1010-1; author reply 1012-3. PubMed ID: 12837841
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    de Bock GH; Tollenaar RA; Papelard H; Vliet Vlieland TP; Devilee P; Cornelisse CJ; Vandenbroucke JP
    J Natl Cancer Inst; 2003 Jul; 95(13):1011-2; author reply 1012-3. PubMed ID: 12837842
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
    J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Rookus MA; Brohet R; van Leeuwen FE
    J Natl Cancer Inst; 2003 Jul; 95(13):1012. PubMed ID: 12837843
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
    Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk reduction works for BRCA mutation carriers--with heavy costs.
    Vanchieri C
    J Natl Cancer Inst; 2005 Jul; 97(14):1032-3. PubMed ID: 16030299
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
    Brohet RM; Goldgar DE; Easton DF; Antoniou AC; Andrieu N; Chang-Claude J; Peock S; Eeles RA; Cook M; Chu C; Noguès C; Lasset C; Berthet P; Meijers-Heijboer H; Gerdes AM; Olsson H; Caldes T; van Leeuwen FE; Rookus MA
    J Clin Oncol; 2007 Sep; 25(25):3831-6. PubMed ID: 17635951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
    Iodice S; Barile M; Rotmensz N; Feroce I; Bonanni B; Radice P; Bernard L; Maisonneuve P; Gandini S
    Eur J Cancer; 2010 Aug; 46(12):2275-84. PubMed ID: 20537530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 11. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptives and breast cancer risk.
    Ansink AC; Burger CW
    J Clin Oncol; 2007 Nov; 25(33):5327; author reply 5327-8. PubMed ID: 18024881
    [No Abstract]   [Full Text] [Related]  

  • 13. [Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].
    Pujol P; This P; Noruzinia M; Stoppa-Lyonnet D; Maudelonde T
    Bull Cancer; 2004; 91(7-8):583-91. PubMed ID: 15381448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
    Grenader T; Peretz T; Lifchitz M; Shavit L
    Breast; 2005 Aug; 14(4):264-8. PubMed ID: 16085232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
    Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
    Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    Nolan E; Vaillant F; Visvader JE; Lindeman GJ
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383640
    [No Abstract]   [Full Text] [Related]  

  • 20. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).
    Chenevix-Trench G; Milne RL; Antoniou AC; Couch FJ; Easton DF; Goldgar DE;
    Breast Cancer Res; 2007; 9(2):104. PubMed ID: 17466083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.